1221485-84-2

Basic information

• Product Name: 2-(2,4-difluorophenylamino)-7-[2S-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one
• Synonyms: 2-(2,4-difluorophenylamino)-7-[2S-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one
• CAS NO: 1221485-84-2
• Molecular Weight: 425.432
• Mol File: 1221485-84-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(2,4-difluorophenylamino)-7-[2S-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,4-difluorophenylamino)-7-[2S-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one(1221485-84-2)
• EPA Substance Registry System: 2-(2,4-difluorophenylamino)-7-[2S-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one(1221485-84-2)

Safety Data

• Hazardous Substances Data: 1221485-84-2(Hazardous Substances Data)

Upstream product

• 871502-87-3 4-bromo-2-formylbenzoic acid 
• 1221485-69-3 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one 
• 4785-56-2 2-formyl-5-methoxy-benzoic acid 
• 1221486-41-4 2-(3-chlorophenethyl)-5-methoxy-benzoic acid 
• 1353948-58-9 2-(3-chlorophenethenyl)-5-methoxy-benzoic acid 
• 1383443-39-7 (R)-2-chloro-7-(2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy-10,11-dihydro-dibenzo[a,d]cyclohepten-5-one 
• 4741-63-3 6-methoxyphthalide 
• 1383443-32-0 2-(2,4-difluorophenylamino)-7-(R-1,2-isopropylidenglycer-3-yl)-10,11-dihydro-dibenzo-[a,d]-cyclohepten-5-one 

Relevant articles and documents

Design, synthesis, and structure–activity relationship study of potent mapk11 inhibitors

Huntington’s disease (HD) is a rare single-gene neurodegenerative disease, which can only be treated symptomatically. Currently, there are no approved drugs for HD on the market. Studies have found that MAPK11 can serve as a potential therapeutic target f

DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS

The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. The